Qvin

Diagnostic infrastructure for women's health.

A vertically integrated platform — collection, lab, software, regulatory — that turns menstrual blood into a recurring, non-invasive sample for screening, monitoring, and biomarker discovery across gynecologic and systemic disease.

Proof points

Regulated, validated, and shipping at scale.

The opportunity

Menstrual blood is the most accessible clinical sample women have ever had.

Over 70% of medical decisions today are driven by lab work. Menstrual blood is biologically rich — endometrial cells, immune components, hormones, and protein biomarkers reflective of both gynecologic and systemic health — and uniquely recurring. The Q-Pad, Qvin's FDA-cleared diagnostic menstrual pad, captures Dried Menstrual Samples (DMS) passively, monthly, at home. The result is a regulated, scalable substrate that supports molecular, chemistry, protein, and multi-omics workflows.

Where to start

Explore the platform.

In the press

Selected coverage.

Full coverage on Media.

References

Sources

  1. U.S. Food & Drug Administration. 510(k) Premarket Notification database — Q-Pad cleared device record. accessdata.fda.gov.
  2. Naseri S, Rosenberg-Hasson Y, Maecker HT, Avrutsky MI, Park CL. Demonstration of menstrual blood as a viable source for screening and diagnostic clinical applications: a pilot study. BMC Women's Health, 2023. bmcwomenshealth.biomedcentral.com.